HAVCR1 and prostate cancer: HAVcR-1 ectodomain levels were decreased in serum samples from the prostate cancer patient group (96.25 ± 32.85 pg/mL) compared to the serum samples from the healthy control group (208.46 ± 58.50 pg/mL), (p < 0.0001), Figure 1A. Moreover, Gleason scores of 6, 7, 8, 9 and 10 regarding the prostate cancer serum samples as well as healthy control serum samples were compared (Figure 1B, Top), showing a significant decrease between the healthy control group (208.46 ± 58.50 pg/mL) and a Gleason score of 6 (14.56 ± 9.564 pg/mL; p = 0.0061), Figure 1B (Bottom).